论文部分内容阅读
目的对胸腺法新联合TC方案治疗中晚期非小细胞肺癌进行诊疗分析。方法对符合治疗研究标准的42例中晚期NSCLC患者,随机分为2组,治疗组(n=21),胸腺法新联合TC方案化疗,和对照组(n=21)仅用TC方案化疗。结果治疗组化疗后CD4和NK细胞活性显著高于化疗前和对照组化疗后水平,治疗组有效率52.4%(11/21),1年生存率为52.6%,对照组有效率42.9%(9/21),1年生存率为38.8%,两组间疗效、毒副反应及1年生存率比较,差异无显著性(P<0.05)。结论胸腺法新联合TC方案化疗能提高肺癌化疗患者机体的免疫功能,改善患者生存质量。
Objective To analyze the diagnosis and treatment of advanced non-small cell lung cancer by thymus combined with TC regimen. Methods Forty-two patients with advanced non-small cell lung cancer (NSCLC) who met the criteria of treatment study were randomly divided into two groups: treatment group (n = 21), thymus combined with TC regimen and control group (n = 21) Results After treatment, the activity of CD4 and NK cells in the treatment group was significantly higher than that in the chemotherapy group and the control group. The effective rate was 52.4% (11/21) in the treatment group, 52.6% in the control group and 42.9% in the control group / 21). The 1-year survival rate was 38.8%. There was no significant difference in efficacy, toxicity and 1-year survival between the two groups (P <0.05). Conclusion Thymus combined with TC regimen chemotherapy can improve the immune function of patients with lung cancer chemotherapy and improve the quality of life of patients.